Skip to content
10-Q

Quarterly Report

Allogene Therapeutics, Inc. ALLO

0001737287-25-000064

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 218.73M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $42.46M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $75.22M
Current Liabilities Q1 2025 · Mar 31, 2025 $30.02M
Current Liabilities Q1 2025 · Dec 31, 2024 $35.52M
Total Liabilities Q1 2025 · Mar 31, 2025 $122.59M
Total Liabilities Q1 2025 · Dec 31, 2024 $126.53M
Current Assets Q1 2025 · Mar 31, 2025 $291.58M
Current Assets Q1 2025 · Dec 31, 2024 $303.39M
Total Assets Q1 2025 · Mar 31, 2025 $507.98M
Total Assets Q1 2025 · Dec 31, 2024 $548.71M
Revenue Q1 2025 · Mar 31, 2025 $0
Revenue Q1 2025 · Mar 31, 2024 $22K
Shares Diluted Q1 2025 · Mar 31, 2024 169.13M sh
Capex Q1 2025 · Mar 31, 2024 $8K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$55.9M
Stockholders Equity Q1 2025 · Mar 31, 2024 $461.37M
Stockholders Equity Q1 2025 · Dec 31, 2023 $512.23M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.38
Eps Basic Q1 2025 · Mar 31, 2024 −$0.38
Sga Expense Q1 2025 · Mar 31, 2024 $17.27M
Rd Expense Q1 2025 · Mar 31, 2024 $52.26M
Net Income Q1 2025 · Mar 31, 2024 −$65M
Operating Income Q1 2025 · Mar 31, 2024 −$69.5M